Pharmacological Inhibition of Myostatin in a Mouse Model of Typical Nemaline Myopathy Increases Muscle Size and Force
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015124 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Johan Lindqvist und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, USA. Hauptthemen laut MEDLINE: Myopathies, Nemaline. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, A Foundation Building Strength and NIH/NIAMS.
Abstract (Originalsprache)
Nemaline myopathy is one of the most common non-dystrophic congenital myopathies. Individuals affected by this condition experience muscle weakness and muscle smallness, often requiring supportive measures like wheelchairs or respiratory support. A significant proportion of patients, approximately one-third, exhibit compound heterozygous nebulin mutations, which usually give rise to the typical form of the disease. Currently, there are no approved treatments available for nemaline myopathy. Our research explored the modulation of myostatin, a negative regulator of muscle mass, in combating the muscle smallness associated with the disease. To investigate the effect of myostatin inhibition, we employed a mouse model with compound heterozygous nebulin mutations that mimic the typical form of the disease. The mice were treated with mRK35, a myostatin antibody, through weekly intraperitoneal injections of 10 mg/kg mRK35, commencing at two weeks of age and continuing until the mice reached four months of age. The treatment resulted in an increase in body weight and an approximate 20% muscle weight gain across most skeletal muscles, without affecting the heart. The minimum Feret diameter of type IIA and IIB fibers exhibited an increase in compound heterozygous mice, while only type IIB fibers demonstrated an increase in wild-type mice. In vitro mechanical experiments conducted on intact extensor digitorum longus muscle revealed that mRK35 augmented the physiological cross-sectional area of muscle fibers and enhanced absolute tetanic force in both wild-type and compound heterozygous mice. Furthermore, mRK35 administration improved grip strength in treated mice. Collectively, these findings indicate that inhibiting myostatin can mitigate the muscle deficits in nebulin-based typical nemaline myopathy, potentially serving as a much-needed therapeutic option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724, USA.
ORCID-Profile: Johan Lindqvist
Förderung
- NIAMS NIH HHS
- A Foundation Building Strength and NIH/NIAMS
Zitieren
APA
Lindqvist, J., & Granzier, H. (2023). Pharmacological Inhibition of Myostatin in a Mouse Model of Typical Nemaline Myopathy Increases Muscle Size and Force. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015124
Vancouver
Lindqvist J, Granzier H. Pharmacological Inhibition of Myostatin in a Mouse Model of Typical Nemaline Myopathy Increases Muscle Size and Force. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015124
BibTeX
@article{Lindqvist2023,
author = {Lindqvist, Johan and Granzier, Henk},
title = {Pharmacological Inhibition of Myostatin in a Mouse Model of Typical Nemaline Myopathy Increases Muscle Size and Force},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015124}
}
EUVIMED